ProCE Banner Activity

Key Updates in Cervical and Ovarian Cancers: IGCS 2022 Annual Meeting

Clinical Thought
Two experts in gynecologic cancers discuss important clinical trial updates, including chemoradiation, PARP inhibition, and checkpoint inhibitors.

Released: November 03, 2022

Expiration: November 02, 2023

Share

Faculty

Susana Banerjee

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Susana Banerjee, MBBS, MA, PhD, FRCP: consultant/advisor/speaker: Amgen, AstraZeneca, Clovis, EMD Serono, Epsilogen, GlaxoSmithKline, ImmunoGen, Merck Sharp & Dohme Corp, Mersana Therapeutics, Novartis, OncXerna, Pfizer, Regeneron, Roche, Seagen, Shattuck Lans, Takeda; researcher: AstraZeneca, GlaxoSmithKline.